Table 3.
Clinical response rates in integrated CANVAS of patients positive for selected baseline isolates at day 3 (E-MITT population)
| Organisma | No. of responders/total (%) |
|
|---|---|---|
| Ceftaroline (n = 400) | V/A (n = 397) | |
| Staphylococcus aureus | 188/246 (76.4) | 156/236a (66.1) |
| MRSA | 85/104 (81.7) | 65/84 (77.4) |
| MSSA | 102/142 (71.8) | 92/153 (60.1) |
| Streptococcus pyogenes | 25/47 (53.2) | 28/49 (57.1) |
| Streptococcus agalactiae | 9/13 (69.2) | 6/7 (85.7) |
| Enterococcus faecalis | 8/13 (61.5) | 6/10 (60.0) |
| Streptococcus anginosus group | 8/9 (88.9) | 6/10 (60.0) |
| Streptococcus dysgalactiae | 6/8 (75.0) | 4/8 (50.0) |
| Escherichia coli | 5/8 (62.5) | 7/13 (53.8) |
| Proteus mirabilis | 7/10 (70.0) | 7/12 (58.3) |
| Klebsiella pneumoniae | 5/9 (55.6) | 1/7 (14.3) |
| Klebsiella oxytoca | 6/8 (75.0) | 3/6 (50.0) |
a
The table lists all Enterobacteriaceae isolates, including those producing extended-spectrum β-lactamases. One patient had both MSSA and MRSA and was counted once in the S. aureus total.